Long-term interferon beta-1b therapy for MS: is routine thyroid assessment always useful?

Area of Science:

• Neurology
• Endocrinology
• Immunology

Background:

• Previous research indicated thyroid dysfunction and autoimmunity in multiple sclerosis (MS) patients treated with interferon-beta 1b (IFN beta-1b) over one year.
• This study investigates the long-term effects of IFN beta-1b on thyroid health in MS patients.

Purpose of the Study:

• To evaluate the long-term evolution of thyroid disease in patients with relapsing-remitting MS undergoing IFN beta-1b therapy.
• To assess the development of new thyroid conditions during extended treatment periods.

Main Methods:

• A cohort of 31 relapsing-remitting MS patients were monitored for three years during IFN beta-1b treatment.
• Systematic thyroid assessments were conducted every 3-6 months, with frequency adjusted based on observed thyroid issues.

Main Results:

• No new thyroid disease cases emerged after the first year of IFN beta-1b treatment.
• Persistent subclinical hypothyroidism was observed only in patients with pre-existing autoimmune thyroiditis (n=2).
• Transient hyperthyroidism cases resolved, and patients remained euthyroid; autoantibody titers were inconsistent in patients without baseline autoimmunity.

Conclusions:

• The risk of thyroid disease associated with IFN beta-1b appears confined to the first year of treatment, especially for those with prior thyroiditis.
• Thyroid dysfunction is generally mild and transient, suggesting targeted monitoring.
• Routine thyroid assessment is recommended primarily for patients with baseline thyroiditis, with serum TSH sufficient for initial screening in the first year.